Last updated: 07/17/2024 15:28:47
A study to evaluate safety and efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects with Anemia Associated with Chronic Kidney Diseases (CKD)
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A 24-week, Phase IIB, Randomized, Controlled, Parallel group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects with Anemia Associated with Chronic Kidney Diseases who are not on Dialysis.
Trial description: This study will be conducted in approximately 228 subjects with anemia associated with CKD who are not on dialysis. Two groups of subjects will be enrolled into the study: Group 1: recombinant human erythropoietin (rhEPO) naive subjects; Group 2: rhEPO users, who are currently receiving rhEPO. Subjects who are rhEPO naive will be randomized to receive either GSK1278863 once daily (QD) or rhEPO in a 3:1 fashion; subjects who are receiving an rhEPO before enrolling (rhEPO users) will be randomized in a 1:1 fashion to GSK1278863 QD or to the control arm. For those randomized to the control arm, the decision around whether the subject requires rhEPO, the selection of the type of rhEPO (if needed) and the choice of rhEPO dose to achieve and maintain Hgb concentrations within the target range should be based on Investigator clinical judgment, with the historical rhEPO dose and the current Hgb value being considered. The study consists of a screening phase of at least 4 weeks, a 24-week treatment phase and a follow-up visit that will occur approximately 4 weeks after completing treatment. It is anticipated that the data generated will enable selection of the starting dose(s) and optimize dose adjustment regimen(s) for Phase 3 clinical trials.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Single (Participant)
Allocation:
Randomized
Primary outcomes:
Summary of hemoglobin (Hgb) concentration at Week 24
Timeframe: Week 24
Secondary outcomes:
Number of participants with hemoglobin (Hgb) in the target range at Week 24
Timeframe: Week 24
Number of participants reaching pre-defined Hgb stopping criteria
Timeframe: Over a period of 24 Weeks
Percent change from Baseline in hepcidin concentration at Week 24
Timeframe: Baseline and Week 24
Maximum observed change from Baseline in serum erythropoietin (EPO)
Timeframe: Baseline to Week 24
Maximum observed percent change from Baseline in Vascular Endothelial Growth Factor (VEGF)
Timeframe: Baseline and up to Week 24
Percentage of time within, below, and above hemoglobin (Hgb) target range, between Weeks 12 and 24
Timeframe: Weeks 12 to 24
Change from Baseline in ferritin concentration at Week 24
Timeframe: Baseline and Week 24
Change from Baseline in transferrin concentration at Week 24
Timeframe: Baseline and Week 24
Percent change from Baseline in transferrin saturation at Week 24
Timeframe: Baseline and Week 24
Change from Baseline in total iron at Week 24
Timeframe: Baseline and Week 24
Change from Baseline in total iron binding capacity (TIBC) at Week 24
Timeframe: Baseline and Week 24
Change from Baseline in reticulocyte hemoglobin (CHr) at Week 24
Timeframe: Baseline and Week 24
Change from Baseline in hematocrit at Week 24
Timeframe: Baseline and Week 24
Change from Baseline in red blood cell count at Week 24
Timeframe: Baseline and Week 24
Change from Baseline in reticulocyte cell count at Week 24
Timeframe: Baseline and Week 24
Concentration of GSK1278863 and relevant metabolites as a population pharmacokinetic endpoint
Timeframe: Day 1 (pre-dose), Week (Wk) 4 (6-12 hour, 7-13 hour, 8-14 hour, 9-15 hour post-dose), and Wk 20 (pre-dose, 1 hour, 2 hour, 3 hour post-dose)
Mean number of dose adjustments up to 24 Weeks
Timeframe: From Week 4 up to 24 Weeks
Number of participants with dose adjustments up to 24 Weeks, as a measure of dose adjustment frequency
Timeframe: From week 4 up to 24 weeks
Timing of dose adjustments at Weeks 4, 8, 12, 16, and 20
Timeframe: From Week 4 up to Week 20
Mean total cumulative dose of GSK1278863 up to 24 Weeks
Timeframe: Up to 24 Weeks
Mean final dose of GSK1278863 up to 24 Weeks
Timeframe: Up to 24 Weeks
Number of hemoglobin (Hgb) excursions
Timeframe: Up to 24 Weeks.
Number of hemoglobin (Hgb) cycles up to 24 Weeks
Timeframe: Up to 24 Weeks
Number of dose cycles up to 24 Weeks
Timeframe: Up to 24 weeks
Number of participants with at least one hemoglobin (Hgb) excursion up to 24 Weeks.
Timeframe: Up to 24 weeks
Number of participants with at least one hemoglobin (Hgb) cycle up to 24 Weeks
Timeframe: Up to 24 weeks
Number of participants with at least one dose cycle up to 24 Weeks
Timeframe: Up to 24 weeks
Number of participants receiving additional therapies of blood transfusions, intravenous (IV) iron or rhEPO at any time post-Baseline
Timeframe: From Day 1 up to Week 28
Number of Weeks dose withheld because hemoglobin (Hgb) exceeded the upper limit
Timeframe: From Week 4 up to Week 24
Interventions:
Drug: GSK1278863
Drug: rhEPO
Enrollment:
252
Observational study model:
Not applicable
Primary completion date:
2015-15-06
Time perspective:
Not applicable
Clinical publications:
Louis Holdstock, Borut Cizman, Amy M. Meadowcroft, Nandita Biswas, Brendan M. Johnson, Delyth Jones, Sung Gyun Kim, Steven Zeig, John J. Lepore, Alexander R. Cobitz .RESUBMISSION: Daprodustat for anemia: a 24-week, open-label, randomized, controlled trial in participants with chronic kidney disease.Clin Kidney J.2018;(sfy013,):1-10.
Louis Holdstock, Borut Cizman, Amy M. Meadowcroft, Nandita Biswas, Brendan M. Johnson, Delyth Jones, Sung Gyun Kim, Steven Zeig, John J. Lepore, Alexander R. Cobitz .RESUBMISSION: Daprodustat for anemia: a 24-week, open-label, randomized, controlled trial in participants with chronic kidney disease.Clin Kidney J.2018;12(1):129–138
DOI: 10.1093/ckj/sfy013
Medical condition
Anaemia
Product
daprodustat
Collaborators
Not applicable
Study date(s)
October 2013 to June 2015
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18 - 99 years
Accepts healthy volunteers
No
- Age: >=18 years of age. (Week -4 verification only)
- Gender: Female and male subjects. (Week -4 verification only) Females: If of childbearing potential, must agree to use one of the approved contraception methods, from Screening until completion of the Follow-up Visit OR Of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy, or oophorectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea. Females on hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use one of the approved contraception methods if they wish to continue their HRT during the study. Otherwise they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.
- Dialysis: On dialysis or planning to initiate dialysis during the study.
- Renal transplant: Pre-emptive or scheduled renal transplant.
Inclusion and exclusion criteria
Inclusion criteria:
- Age: >=18 years of age. (Week -4 verification only)
- Gender: Female and male subjects. (Week -4 verification only) Females: If of childbearing potential, must agree to use one of the approved contraception methods, from Screening until completion of the Follow-up Visit OR Of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy, or oophorectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea. Females on hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use one of the approved contraception methods if they wish to continue their HRT during the study. Otherwise they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.
- Corrected QT interval (QTc): Bazett’s Correction of QT Interval (QTcB) <470 milliseconds (msec) or QTcB <480 msec in subjects with bundle branch block. There is no QTc criterion for subjects with a predominantly paced rhythm.
- CKD stage: Kidney Disease Outcomes Quality Initiative (KDOQI) CKD stages 3/4/5 defined by electronic estimated glomerular filtration rate (eGFR) using the CKD Epidemiology Collaboration (CKD-EPI) formula.
- Hgb: Group 1 (rhEPO naïve): Baseline Hgb of 8.0-11.0 g/dL (inclusive) (USA sites only: 8.0-10.0 g/dL, inclusive); Group 2 (rhEPO users): Baseline Hgb of 9.0-11.5 g/dL (inclusive) (USA sites only: 9.0-10.5, inclusive).
- Stable rhEPO dose for rhEPO users: Group 2 subjects must be using the same rhEPO (epoetins or their biosimilars, or darbepoetin) with total weekly doses that varied by no more than 50% during the 4 weeks prior to Week -4. At Day 1 (randomization), confirm that total weekly doses varied by no more than 50% during the screening period.
- Oral iron therapy: If on oral iron, then doses must not be changed for the 4 weeks prior to Week -4, during the screening phase, and through the first 4 weeks after Randomization.
Exclusion criteria:
- Dialysis: On dialysis or planning to initiate dialysis during the study.
- Renal transplant: Pre-emptive or scheduled renal transplant.
- High rhEPO dose: An epoetin dose of >=360 IU/kg/week intravenous (IV) or >=250 IU/kg/week subcutaneous (SC) or darbepoetin dose of >=1.8 microgram per kilogram per week (mcg/kg/week) IV or SC within the prior 8 weeks through Day 1 (randomization).
- Use of methoxy polyethylene glycol epoetin beta within the prior 8 weeks through Day 1 (randomization).
- IV iron therapy: Use of IV iron for 4 weeks prior to Screening Week -4, during the screening phase, and through the first 4 weeks after Randomization
- Vitamin B12: Below the lower limit of the reference range (may rescreen in a minimum of 8 weeks).
- Folate: <2.0 nanogram per millilitre (ng/mL) (<4.5 nanomoles per liter [nmol/L]) (may rescreen in a minimum of 4 weeks).
- Ferritin: <40 ng/mL (<40 mcg/L).
- Transferrin saturation (TSAT): Below the lower limit of the reference range
- Myocardial infarction or acute coronary syndrome: Within the 8 weeks prior to Screening through Day 1 (randomization).
- Stroke or transient ischemic attack: Within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).
- Heart failure: Class III/IV heart failure as defined by the New York Heart Association (NYHA) functional classification system diagnosed prior to Week -4 Screening through Day 1 (randomization), symptomatic right heart failure diagnosed prior to Week -4 Screening through Day 1 (randomization).
- Uncontrolled hypertension: Defined as diastolic blood pressure (DBP) >100 mmHg or systolic blood pressure (SBP) >170 mmHg at Week -4 and reconfirmed at Day 1.
- Thrombotic Disease: History of thrombotic disease (e.g., venous thrombosis such as deep vein thrombosis or pulmonary embolism, or arterial thrombosis such as new onset or worsening limb ischemia requiring intervention), except vascular access thrombosis within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).
- Ophthalmology disease: Meeting any ophthalmologic-related exclusion criteria determined at the Screening ophthalmology exam.
- Inflammatory disease: Active chronic inflammatory disease that could impact erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis, celiac disease) diagnosed prior to Week -4 Screening through Day 1 (randomization).
- Hematological disease: Any hematological disease including those affecting platelets, white or red blood cells (e.g. sickle cell anemia, myelodysplastic syndromes, hematological malignancy, myeloma, hemolytic anemia and thalassemia), coagulation disorders (e.g., antiphospholipid syndrome, Protein C or S deficiency), or any other cause of anemia other than renal disease diagnosed prior to Week -4 Screening through Day 1 (randomization).
- Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert’s syndrome or asymptomatic gallstones) or evidence at Screening of abnormal liver function tests [alanine transaminase (ALT) or aspartate transaminase (AST) >2.0 x upper limit of normal (ULN) or total bilirubin >1.5 x ULN]; or other hepatic abnormalities that in the opinion of the investigator would preclude the subject from participation in the study.
- Major surgery: Major surgery (excluding vascular access surgery) within the prior 8 weeks, during the Week -4 Screening phase or planned during the study.
- Transfusion: Blood transfusion within the prior 8 weeks, during the Week -4 Screening phase or an anticipated need for blood transfusion during the study.
- Gastrointestinal (GI) Bleeding: Evidence of actively bleeding peptic, duodenal, or esophageal ulcer disease OR clinically significant GI bleeding within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).
- Acute infection: Clinical evidence of acute infection or history of infection requiring IV antibiotic therapy within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).
- Malignancy: Subjects with a history of malignancy within the prior 5 years, who receiving treatment for cancer, or who have a strong family history of cancer (e.g., familial cancer disorders); with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated prior to Week -4 Screening through Day 1 (randomization).
- Severe allergic reactions: History of severe allergic or anaphylactic reactions or hypersensitivity to excipients in the investigational product (see GSK1278863 IB for list of excipients and rhEPO (refer to local product labelling for details).
- Drugs and supplements: Use of any prescription or non-prescription drugs or dietary supplements that are prohibited from Week -4 Screening until the Follow-up Visit.
- Prior investigational product exposure: The Subject has participated in a clinical trial and has received an experimental investigational product within the prior 30 days from Week -4 Screening through Day 1 (randomization).
- Other Conditions: Any other condition, clinical or laboratory abnormality, or examination finding that the Investigator considers would put the subject at unacceptable risk.
- Patient participation: Unwillingness or inability of the subject to follow the procedures or lifestyle or dietary restrictions outlined in the protocol.
- Pregnancy or Lactation: Pregnant females as determined by positive urine human chorionic gonadotropin (hCG) test OR women who are lactating at Week -4 Screening or during the trial.
Trial location(s)
Location
GSK Investigational Site
Adelaide, South Australia, Australia, 5000
Status
Study Complete
Location
GSK Investigational Site
Anyang-Si Gyeonggi-do, South Korea, 431-070
Status
Study Complete
Location
GSK Investigational Site
Azusa, California, United States, 91702
Status
Study Complete
Location
GSK Investigational Site
Bethlehem, Pennsylvania, United States, 18017
Status
Study Complete
Location
GSK Investigational Site
Charlotte, North Carolina, United States
Status
Study Complete
Location
GSK Investigational Site
Corsicana, Texas, United States, 75110
Status
Study Complete
Location
GSK Investigational Site
Demmin, Mecklenburg-Vorpommern, Germany, 17109
Status
Study Complete
Location
GSK Investigational Site
Duesseldorf, Nordrhein-Westfalen, Germany, 40210
Status
Study Complete
Location
GSK Investigational Site
Evergreen Park, Illinois, United States, 60805
Status
Study Complete
Location
GSK Investigational Site
Farmington, Missouri, United States, 63640
Status
Study Complete
Location
GSK Investigational Site
Knoxville, Tennessee, United States, 37923
Status
Study Complete
Location
GSK Investigational Site
La Mesa, California, United States, 91942
Status
Study Complete
Location
GSK Investigational Site
Laguna Hills, California, United States, 92653
Status
Study Complete
Location
GSK Investigational Site
Lauderdale Lakes, Florida, United States, 33313
Status
Study Complete
Location
GSK Investigational Site
Liverpool, New South Wales, Australia, 2170
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90022
Status
Study Complete
Location
GSK Investigational Site
Marianske Lazne, Czech Republic, 353 01
Status
Study Complete
Location
GSK Investigational Site
Nedlands, Western Australia, Australia, 6009
Status
Study Complete
Location
GSK Investigational Site
Pembroke Pines, Florida, United States, 33028
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78229
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92103
Status
Study Complete
Location
GSK Investigational Site
San Dimas, California, United States, 91773
Status
Study Complete
Location
GSK Investigational Site
San Sebastian de los Reyes, Spain, 28702
Status
Study Complete
Location
GSK Investigational Site
Savannah, Georgia, United States, 31406
Status
Study Complete
Location
GSK Investigational Site
Shreveport, Louisiana, United States, 71101
Status
Study Complete
Location
GSK Investigational Site
Uniontown, Pennsylvania, United States, 15401
Status
Study Complete
Location
GSK Investigational Site
West Hills, California, United States, 91307
Status
Study Complete
Location
GSK Investigational Site
Westmead, New South Wales, Australia, 2145
Status
Study Complete
Study documents
Study report synopsis
Available language(s): English
Protocol
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2015-15-06
Actual study completion date
2015-15-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website